3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
17
Myelodysplastic Syndromes
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Hematologic Neoplasms
9
Myeloproliferative Disorders
8
Multiple Myeloma
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Hodgkin Disease
7
Lymphoma, Non-Hodgkin
6
Graft vs Host Disease
6
Waldenstrom Macroglobulinemia
5
Lymphoma
5
Burkitt Lymphoma
5
Recurrence
4
Primary Myelofibrosis
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Lymphoma, Mantle-Cell
4
Leukemia, Prolymphocytic
4
Leukemia, Myelomonocytic, Chronic
4
Skin Neoplasms
3
Sarcoma
3
Rhabdomyosarcoma
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Biphenotypic, Acute
3
Leukemia
3
Bronchiolitis Obliterans Syndrome
3
Interventions
Magnetic Resonance Spectroscopy
9
Cyclophosphamide
7
X-Rays
6
Temozolomide
6
Specimen Handling
6
Phantoms, Imaging
6
Biopsy
6
Nuclear Medicine Department, Hospital
5
Etoposide
5
Nivolumab
4
Bevacizumab
4
Radiation
3
Irinotecan
3
Automobiles
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
lutetium Lu 177 dotatate
2
larotrectinib
2
ivosidenib
2
etoposide phosphate
2
erdafitinib
2
ensartinib
2
abemaciclib
2
Watchful Waiting
2
Radiotherapy
2
ONC206
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ependymoma
×
Sirolimus
×
1 year
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled